Trial Profile
An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Burosumab (Primary)
- Indications X-linked dominant hypophosphataemic rickets
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Kyowa Kirin
- 23 Mar 2021 Results of 3- year safety and efficacy presented at the 103rd Annual Meeting of the Endocrine Society.
- 30 Sep 2019 Status changed from active, no longer recruiting to completed.
- 20 Dec 2018 Planned End Date changed from 16 Aug 2019 to 1 Sep 2019.